Literature DB >> 7972018

The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.

D J Kuter1, D L Beeler, R D Rosenberg.   

Abstract

The circulating blood platelet is produced by the bone marrow megakaryocyte. In response to a decrease in the platelet count, megakaryocytes increase in number and ploidy. Although this feedback loop has long been thought to be mediated by a circulating hematopoietic factor, no such factor has been purified. Using a model of thrombocytopenia in sheep, we have identified an active substance called megapoietin, which stimulated an increase in the number and ploidy of megakaryocytes in bone marrow culture. Circulating levels of this factor could be quantified with this assay and were found to be inversely proportional to the platelet count of the sheep. Levels increased from < 0.26 pM in normal sheep to 25-40 pM in thrombocytopenic sheep. From large amounts of thrombocytopenic sheep plasma we have purified a 31,200-Da protein and found that it retained the ability to stimulate both megakaryocyte number and ploidy in vitro. Injection of partially purified megapoietin into rats stimulated a 24% increase in megakaryocyte number and a 60% increase in mean ploidy as well as a 77% increase in the platelet count. Sheep platelets bound megapoietin and the amount of platelets required to eliminate half the activity in vitro was close to the amount associated with this same level of activity in vivo. We believe that megapoietin is the physiologically relevant mediator of megakaryocyte growth and platelet production. Moreover, our data suggest that the level of megapoietin is directly determined by the ability of platelets to remove megapoietin from the circulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7972018      PMCID: PMC45175          DOI: 10.1073/pnas.91.23.11104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  10 in total

1.  Ultrastructural changes of endothelium associated with thrombocytopenia.

Authors:  C S Kitchens; L Weiss
Journal:  Blood       Date:  1975-10       Impact factor: 22.113

Review 2.  Erythropoietin titers in health and disease.

Authors:  A J Erslev
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

3.  Is interleukin 6 the physiological regulator of thrombopoiesis?

Authors:  J E Straneva; K W van Besien; G Derigs; R Hoffman
Journal:  Exp Hematol       Date:  1992-01       Impact factor: 3.084

4.  Analysis of megakaryocyte ploidy in rat bone marrow cultures.

Authors:  D J Kuter; S M Greenberg; R D Rosenberg
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

5.  Kinetics of thrombopoiesis.

Authors:  L A Harker
Journal:  J Clin Invest       Date:  1968-03       Impact factor: 14.808

6.  Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.

Authors:  F J de Sauvage; P E Hass; S D Spencer; B E Malloy; A L Gurney; S A Spencer; W C Darbonne; W J Henzel; S C Wong; W J Kuang
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

7.  Two-color flow cytometric measurement of DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions.

Authors:  C W Jackson; L K Brown; B C Somerville; S A Lyles; A T Look
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

8.  Regulation of megakaryocyte ploidy in vivo in the rat.

Authors:  D J Kuter; R D Rosenberg
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

9.  Transforming growth factor beta inhibits megakaryocyte growth and endomitosis.

Authors:  D J Kuter; D M Gminski; R D Rosenberg
Journal:  Blood       Date:  1992-02-01       Impact factor: 22.113

10.  Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit.

Authors:  D J Kuter; R D Rosenberg
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

  10 in total
  59 in total

1.  Suspects in the tale of lupus-associated thrombocytopenia.

Authors:  P D Ziakas; J G Routsias; S Giannouli; A Tasidou; A G Tzioufas; M Voulgarelis
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 2.  Historical review: megakaryopoiesis and thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

Review 3.  Hematopoietic cytokines.

Authors:  Donald Metcalf
Journal:  Blood       Date:  2008-01-15       Impact factor: 22.113

4.  Inhibition of GSK-3beta promotes survival and proliferation of megakaryocytic cells through a beta-catenin-independent pathway.

Authors:  Mie Soda; Karl Willert; Kenneth Kaushansky; Amy E Geddis
Journal:  Cell Signal       Date:  2008-09-06       Impact factor: 4.315

Review 5.  Thrombopoietin and platelet production in chronic immune thrombocytopenia.

Authors:  David J Kuter; Terry B Gernsheimer
Journal:  Hematol Oncol Clin North Am       Date:  2009-12       Impact factor: 3.722

6.  Long-term efficacy of pegylated recombinant human megakaryocyte growth and development factor in therapy of aplastic anemia.

Authors:  Yuji Yonemura; Hirosada Miyake; Norio Asou; Hiroaki Mitsuya
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

Review 7.  Thrombopoietin and platelet development.

Authors:  K Kaushansky
Journal:  West J Med       Date:  1996-03

Review 8.  It's reticulated: the liver at the heart of atherosclerosis.

Authors:  Prabhakara R Nagareddy; Sunil K Noothi; Michelle C Flynn; Andrew J Murphy
Journal:  J Endocrinol       Date:  2018-05-02       Impact factor: 4.286

9.  Megakaryocytes and platelets from a novel human adipose tissue-derived mesenchymal stem cell line.

Authors:  Keiichi Tozawa; Yukako Ono-Uruga; Masaki Yazawa; Taisuke Mori; Mitsuru Murata; Shinichiro Okamoto; Yasuo Ikeda; Yumiko Matsubara
Journal:  Blood       Date:  2018-11-28       Impact factor: 22.113

Review 10.  Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Authors:  Roberto Stasi; Maria L Evangelista; Sergio Amadori
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.